MARKET

NEOS

NEOS

Neos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.490
-0.010
-0.67%
Closed 16:00 12/10 EST
OPEN
1.513
PREV CLOSE
1.500
HIGH
1.513
LOW
1.430
VOLUME
156.31K
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
1.130
MARKET CAP
74.60M
P/E (TTM)
-3.0321
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NEOS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NEOS News

  • Edited Transcript of NEOS earnings conference call or presentation 8-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/17 02:39
  • Neos Therapeutics: Q3 Earnings Strengthens Investment Thesis
  • Seeking Alpha - Article.11/12 16:48
  • Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/08 21:22
  • Neos Therapeutics, Inc. 2019 Q3 - Results - Earnings Call Presentation
  • Seeking Alpha - Article.11/08 18:40

More

Industry

Pharmaceuticals
-0.53%
Pharmaceuticals & Medical Research
-0.29%

Hot Stocks

Name
Price
%Change

About NEOS

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
More

Webull offers Neos Therapeutics Inc (NEOS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.